Anti-Histone H3 (citrulline R2 + R8 + R17) antibody [RM1001] (Ab281584)

特异性

Treatment is required for detection of the target protein. See Protocol section for detailed information. 更多详细信息请参阅 Protocol 部分.

Product Specifications Anti-Histone H3 (citrulline R2 + R8 + R17) antibody [RM1001] (ab281584) is a recombinant rabbit multiclonal antibody which is comprised of multiple monoclonal antibodies targeting different epitopes and recapitulating the performance of a polyclonal. Each component clone was developed by Abcam using patented rabbit monoclonal antibody technology. Anti-Histone H3 (citrulline R2 + R8 + R17) antibody [RM1001] (ab281584) is validated for use in Dot blot, Flow Cyt (Intra), ICC/IF, IP, PepArr and WB in human, mouse and rat samples. Anti-Histone H3 (citrulline R2 + R8 + R17) antibody [RM1001] (ab281584) specifically detects Histone H3 (citrulline R2 + R8 + R17) (UniProt ID: P68431; Molecular weight: 15kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Quality and Validation Abcams high quality manufacturing and validation processes ensure anti-Histone H3 (citrulline R2 + R8 + R17) antibody [RM1001] (ab281584) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Related Products Conjugation-ready, carrier free format available for antibody clone RM1001 - ab283863. Target Information This antibody is a key tool in cancer research, particularly in understanding histone citrullination's role in tumorigenesis, and is widely used in studies of gene expression, DNA repair, and autoimmune diseases like rheumatoid arthritis and lupus, involving protein arginine deiminases (PADs) and NETosis. Histone hypercitrullination is reported to play a role the progression of various cancers, including multiple myeloma, acute myeloid leukemia, lung cancer, and hepatocellular carcinoma. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents.